M Azzouz

Summary

Affiliation: Medawar Centre
Country: UK

Publications

  1. ncbi Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model
    Mimoun Azzouz
    Oxford BioMedica UK Ltd, Oxford OX4 4GA, United Kingdom
    J Neurosci 22:10302-12. 2002
  2. pmc Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy
    Mimoun Azzouz
    Oxford BioMedicaLtd, Medwar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA, UK
    J Clin Invest 114:1726-31. 2004
  3. ncbi Non-primate EIAV-based lentiviral vectors as gene delivery system for motor neuron diseases
    M Azzouz
    Oxford BioMedica UK Ltd, The Oxford Science Park, Medawar Centre, Oxford OX4 4GA, UK
    Curr Gene Ther 4:277-86. 2004
  4. ncbi Lentiviral vectors for treating and modeling human CNS disorders
    Mimoun Azzouz
    Oxford BioMedica UK Ltd, The Oxford Science Park, Medawar Center, Oxford OX4 4GA, UK
    J Gene Med 6:951-62. 2004
  5. ncbi VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model
    Mimoun Azzouz
    Oxford BioMedica plc, The Oxford Science Park, Medawar Centre, Oxford OX4 4GA, UK
    Nature 429:413-7. 2004
  6. ncbi Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery
    N D Mazarakis
    Oxford BioMedica UK Ltd, Medawar Centre, The Oxford Science Park, Oxford OX4 4GA, UK
    Hum Mol Genet 10:2109-21. 2001
  7. ncbi Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model
    G Scott Ralph
    Oxford BioMedica Ltd, Medawar Centre, The Oxford Science Park, Oxford, OX4 4GA, UK
    Nat Med 11:429-33. 2005
  8. ncbi Transduction patterns of pseudotyped lentiviral vectors in the nervous system
    Liang Fong Wong
    Neurobiology Group, Oxford BioMedica UK Ltd, Medawar Centre, Oxford OX4 4GA, United Kingdom
    Mol Ther 9:101-11. 2004
  9. ncbi Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord
    Liang Fong Wong
    Oxford BioMedica UK Ltd, Medawar Centre, Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GA, UK
    Nat Neurosci 9:243-50. 2006
  10. ncbi Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors
    G Scott Ralph
    Oxford BioMedica plc, The Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK
    Clin Sci (Lond) 110:37-46. 2006

Collaborators

Detail Information

Publications16

  1. ncbi Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model
    Mimoun Azzouz
    Oxford BioMedica UK Ltd, Oxford OX4 4GA, United Kingdom
    J Neurosci 22:10302-12. 2002
    ....
  2. pmc Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy
    Mimoun Azzouz
    Oxford BioMedicaLtd, Medwar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA, UK
    J Clin Invest 114:1726-31. 2004
    ..Further extension of survival by SMN expression constructs will likely require a knowledge of when and/or where high levels of SMN are needed...
  3. ncbi Non-primate EIAV-based lentiviral vectors as gene delivery system for motor neuron diseases
    M Azzouz
    Oxford BioMedica UK Ltd, The Oxford Science Park, Medawar Centre, Oxford OX4 4GA, UK
    Curr Gene Ther 4:277-86. 2004
    ..The prospects for the clinical evaluation of lentiviral vectors for the treatment of human motor neuron disease will be outlined...
  4. ncbi Lentiviral vectors for treating and modeling human CNS disorders
    Mimoun Azzouz
    Oxford BioMedica UK Ltd, The Oxford Science Park, Medawar Center, Oxford OX4 4GA, UK
    J Gene Med 6:951-62. 2004
    ..The prospects for clinical application of lentiviral vectors for the treatment of PD and MNDs will also be outlined...
  5. ncbi VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model
    Mimoun Azzouz
    Oxford BioMedica plc, The Oxford Science Park, Medawar Centre, Oxford OX4 4GA, UK
    Nature 429:413-7. 2004
    ..VEGF treatment increased the life expectancy of ALS mice by 30 per cent without causing toxic side effects, thereby achieving one of the most effective therapies reported in the field so far...
  6. ncbi Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery
    N D Mazarakis
    Oxford BioMedica UK Ltd, Medawar Centre, The Oxford Science Park, Oxford OX4 4GA, UK
    Hum Mol Genet 10:2109-21. 2001
    ....
  7. ncbi Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model
    G Scott Ralph
    Oxford BioMedica Ltd, Medawar Centre, The Oxford Science Park, Oxford, OX4 4GA, UK
    Nat Med 11:429-33. 2005
    ..These data are the first to show a substantial extension of survival in an animal model of a fatal, dominantly inherited neurodegenerative condition using RNAi and provide the highest therapeutic efficacy observed in this field to date...
  8. ncbi Transduction patterns of pseudotyped lentiviral vectors in the nervous system
    Liang Fong Wong
    Neurobiology Group, Oxford BioMedica UK Ltd, Medawar Centre, Oxford OX4 4GA, United Kingdom
    Mol Ther 9:101-11. 2004
    ..The differences in transduction efficiencies and retrograde transport conferred by these envelope glycoproteins present novel opportunities in designing therapeutic strategies for different neurological diseases...
  9. ncbi Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord
    Liang Fong Wong
    Oxford BioMedica UK Ltd, Medawar Centre, Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GA, UK
    Nat Neurosci 9:243-50. 2006
    ..These findings show that RARbeta2 induces axonal regeneration programs within injured neurons and may thus offer new therapeutic opportunities for CNS regeneration...
  10. ncbi Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors
    G Scott Ralph
    Oxford BioMedica plc, The Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK
    Clin Sci (Lond) 110:37-46. 2006
    ....
  11. ncbi Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector
    Mimoun Azzouz
    Oxford BioMedica UK Ltd, The Oxford Science Park, Medawar Center, Oxford OX4 4GA, UK
    Neuroreport 15:985-90. 2004
    ..GDNF delivery led to extensive expression of GDNF protein within the striatum. In addition, near complete protection against dopaminergic cell death was observed in the GDNF-treated group...
  12. ncbi Therapeutic gene silencing in neurological disorders, using interfering RNA
    G Scott Ralph
    Oxford BioMedica, Ltd, Medawar Centre, Robert Robinson Avenue, Oxford Science Park, OX4 4GA Oxford, UK
    J Mol Med (Berl) 83:413-9. 2005
    ..Here we review the advancement of RNAi technology for therapeutic application and highlight the potential of targeted gene silencing for the treatment of neurodegenerative diseases...
  13. ncbi Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model
    Eilis Dowd
    Brain Repair Group, School of Biosciences, Cardiff University, Wales, UK
    Eur J Neurosci 22:2587-95. 2005
    ..This study confirms that GDNF can protect against 6-OHDA-induced impairments in complex as well as simple behaviours, and reinforces the use of EIAV-based vectors for the treatment of PD...
  14. ncbi Trophic activity of Rabies G protein-pseudotyped equine infectious anemia viral vector mediated IGF-I motor neuron gene transfer in vitro
    Qingshan Teng
    Department of Neuroscience and Center for Neurological Restoration, Lerner Research Institute, Cleveland Clinic Foundation, NB2 126, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Neurobiol Dis 20:694-700. 2005
    ..01). The enhanced motor neuron tropism of RabG.EIAV previously demonstrated in vivo, together with the trophic effects of RabG.EIAV-IGF-I MN gene expression may lend this vector to therapeutic application in motor neuron disease...
  15. ncbi Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1(G93A) transgenic mice
    Sandrine Guillot
    Institute of Neurosciences, Swiss Federal Institute of Technology Lausanne, EPFL, 1015 Lausanne, Switzerland
    Neurobiol Dis 16:139-49. 2004
    ..The differential effect of GDNF on facial nucleus versus spinal motoneurons suggests different vulnerability of motoneurons in ALS...
  16. ncbi Gene Therapy for ALS: progress and prospects
    Mimoun Azzouz
    Academic Unit of Neurology, Medical School, The University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
    Biochim Biophys Acta 1762:1122-7. 2006
    ..The prospects for the clinical evaluation of lentiviral vectors for the treatment of human motor neuron disease will be outlined...